Skip to main content
Premium Trial:

Request an Annual Quote

Sequentify Raises $7M, Exits Stealth Mode

NEW YORK – Israeli genomic sequencing company Sequentify emerged from stealth mode with $7 million in raised funds. Led by venture firm OurCrowd, the capital will be used to accelerate R&D, delivery, and go-to-market plans for the company, Sequentify said.

Founded in 2021 as a Weizmann Institute of Science spinout, Sequentify was built on a technology developed by cofounders Tamir Biezuner and Tom Fleischer at the laboratory of Liran Shlush.

The Rehovot, Israel-based startup claimed in a statement that its proprietary InfiniSeq technology condenses sample preparation time to "only 3.5 hours from DNA to sequencing, with one-tube reaction, full automation support, and dramatic cost reduction." The technology is also adjustable to most sequencing instruments and fits into any lab workflow, thus enabling full integration into laboratories, the firm said.

Based on the InfiniSeq platform, Sequentify's NGS products include COVID-19 surveillance, cancer diagnostics, and carrier screening, with multiple hospitals and labs as customers already, the company said.

"Sequentify enables DNA screening at scale with the goal of making genomics as common and affordable as testing for blood counts," Sequentify Cofounder and CEO Ophir Herbst said in a statement.